These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 12215497)

  • 1. The binding protein of corticotropin-releasing factor: ligand-binding site and subunit structure.
    Jahn O; Eckart K; Brauns O; Tezval H; Spiess J
    Proc Natl Acad Sci U S A; 2002 Sep; 99(19):12055-60. PubMed ID: 12215497
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Impact of N-terminal domains for corticotropin-releasing factor (CRF) receptor-ligand interactions.
    Klose J; Fechner K; Beyermann M; Krause E; Wendt N; Bienert M; Rudolph R; Rothemund S
    Biochemistry; 2005 Feb; 44(5):1614-23. PubMed ID: 15683245
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A single amino acid serves as an affinity switch between the receptor and the binding protein of corticotropin-releasing factor: implications for the design of agonists and antagonists.
    Eckart K; Jahn O; Radulovic J; Tezval H; van Werven L; Spiess J
    Proc Natl Acad Sci U S A; 2001 Sep; 98(20):11142-7. PubMed ID: 11572971
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding differences of human and amphibian corticotropin-releasing factor type 1 (CRF(1)) receptors: identification of amino acids mediating high-affinity astressin binding and functional antagonism.
    Dautzenberg FM; Wille S
    Regul Pept; 2004 May; 118(3):165-73. PubMed ID: 15003833
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Corticotropin releasing factor (CRF) binding protein: a novel regulator of CRF and related peptides.
    Behan DP; De Souza EB; Lowry PJ; Potter E; Sawchenko P; Vale WW
    Front Neuroendocrinol; 1995 Oct; 16(4):362-82. PubMed ID: 8557170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Characterization of peptide-protein interactions using photoaffinity labeling and LC/MS.
    Jahn O; Eckart K; Tezval H; Spiess J
    Anal Bioanal Chem; 2004 Feb; 378(4):1031-6. PubMed ID: 14668969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Alanine scanning mutagenesis of the second extracellular loop of type 1 corticotropin-releasing factor receptor revealed residues critical for peptide binding.
    Gkountelias K; Tselios T; Venihaki M; Deraos G; Lazaridis I; Rassouli O; Gravanis A; Liapakis G
    Mol Pharmacol; 2009 Apr; 75(4):793-800. PubMed ID: 19124613
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ligand affinity for amino-terminal and juxtamembrane domains of the corticotropin releasing factor type I receptor: regulation by G-protein and nonpeptide antagonists.
    Hoare SR; Sullivan SK; Schwarz DA; Ling N; Vale WW; Crowe PD; Grigoriadis DE
    Biochemistry; 2004 Apr; 43(13):3996-4011. PubMed ID: 15049707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Photoaffinity cross-linking of the corticotropin-releasing factor receptor type 1 with photoreactive urocortin analogues.
    Kraetke O; Holeran B; Berger H; Escher E; Bienert M; Beyermann M
    Biochemistry; 2005 Nov; 44(47):15569-77. PubMed ID: 16300406
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Three-amino acid motifs of urocortin II and III determine their CRF receptor subtype selectivity.
    Jahn O; Tezval H; van Werven L; Eckart K; Spiess J
    Neuropharmacology; 2004 Aug; 47(2):233-42. PubMed ID: 15223302
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cloning and characterization of the cDNAs for human and rat corticotropin releasing factor-binding proteins.
    Potter E; Behan DP; Fischer WH; Linton EA; Lowry PJ; Vale WW
    Nature; 1991 Jan; 349(6308):423-6. PubMed ID: 1846945
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticotropin-releasing factor binding protein--a ligand trap?
    Jahn O; Radulovic J; Stiedl O; Tezval H; Eckart K; Spiess J
    Mini Rev Med Chem; 2005 Oct; 5(10):953-60. PubMed ID: 16250837
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity.
    Hoare SR; Sullivan SK; Fan J; Khongsaly K; Grigoriadis DE
    Peptides; 2005 Mar; 26(3):457-70. PubMed ID: 15652653
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ligand requirements of the human corticotropin-releasing factor-binding protein.
    Sutton SW; Behan DP; Lahrichi SL; Kaiser R; Corrigan A; Lowry P; Potter E; Perrin MH; Rivier J; Vale WW
    Endocrinology; 1995 Mar; 136(3):1097-102. PubMed ID: 7867564
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Distribution of corticotropin-releasing factor binding protein-immunoreactivity in the rat hypothalamus: association with corticotropin-releasing factor-, urocortin 1- and vimentin-immunoreactive fibres.
    Henry BA; Lightman SL; Lowry CA
    J Neuroendocrinol; 2005 Mar; 17(3):135-44. PubMed ID: 15796765
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of corticotropin releasing factor. Receptor selectivity of corticotropin releasing factor related peptides.
    Mazur AW; Wang F; Tscheiner M; Donnelly E; Isfort RJ
    J Med Chem; 2004 Jun; 47(13):3450-4. PubMed ID: 15189041
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Photolabeling study of the ligand binding domain of natriuretic peptide receptor A: development of a model.
    Jossart C; Coupal M; McNicoll N; Fournier A; Wilkes BC; De Léan A
    Biochemistry; 2005 Feb; 44(7):2397-408. PubMed ID: 15709752
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure-activity studies on the corticotropin releasing factor antagonist astressin, leading to a minimal sequence necessary for antagonistic activity.
    Rijkers DT; Kruijtzer JA; van Oostenbrugge M; Ronken E; den Hartog JA; Liskamp RM
    Chembiochem; 2004 Mar; 5(3):340-8. PubMed ID: 14997526
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Isoform specific differences in binding of a dual-specificity A-kinase anchoring protein to type I and type II regulatory subunits of PKA.
    Burns LL; Canaves JM; Pennypacker JK; Blumenthal DK; Taylor SS
    Biochemistry; 2003 May; 42(19):5754-63. PubMed ID: 12741833
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacological characterization of recombinant rat corticotropin releasing factor binding protein using different sauvagine analogs.
    Jahn O; Eckart K; Sydow S; Hofmann BA; Spiess J
    Peptides; 2001 Jan; 22(1):47-56. PubMed ID: 11179597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.